Rishi Kakar, MD

Rishi Kakar, MD, is the chief scientific officer and medical director of Segal Trials.

Articles by Rishi Kakar, MD

Thumbnail for schizophrenia special report around approval of Cobenfy.

Unmet Needs, Future Research in Schizophrenia and Muscarinic Agonists

BySam Clark, MD, PhD,Andrew Cutler, MD,Rishi Kakar, MD

October 8th 2024

In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.

Balancing the Benefits and Risks of Xanomeline and Trospium Chloride Capsules

BySam Clark, MD, PhD,Andrew Cutler, MD,Rishi Kakar, MD

October 8th 2024

In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.

Applying EMERGENT Trial Results to Real-World Clinical Practice for Schizophrenia

BySam Clark, MD, PhD,Andrew Cutler, MD,Rishi Kakar, MD

October 8th 2024

In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.

Mechanism of Action of Xanomeline and Trospium Chloride Capsules in Schizophrenia

BySam Clark, MD, PhD,Andrew Cutler, MD,Rishi Kakar, MD

October 8th 2024

In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.

Embracing New Therapies in Schizophrenia Management: Introductions

BySam Clark, MD, PhD,Andrew Cutler, MD,Rishi Kakar, MD

October 8th 2024

In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.